Source: BioSig Technologies, Inc.
BioSig Technologies, Inc. (OTCQB: BSGM) today announced it has signed an agreement to initiate development of its PURE EPTM
high fidelity cardiac electrophysiology (EP) signal acquisition and
analysis system with Minnetronix, an award-winning medical technology
development and manufacturing firm.
Greg Cash, President and
Chief Executive Officer of BioSig Technologies, stated, “We are very
pleased to begin this relationship with Minnetronix, who has proven to
be a leader in taking innovative medical technology through the
development process and into manufacturing in a timely manner. It is our
goal to help patients through positively impacting the diagnosis and
treatment of complex cardiac arrhythmias as soon as we possibly can.”
“We
are excited to work with an advanced cardiac electrophysiology company
like BioSig,” said Jeremy Maniak, Minnetronix Chief Operating Officer.
“Minnetronix has developed numerous technologies in the
electrophysiology field, including mapping and ablation, which positions
us well to bring leading-edge technologies like the PURE EP System to
the market quickly.”
About BioSig Technologies
BioSig
Technologies is a medical device company that is developing a
proprietary technology platform designed to improve the $3 billion EP
marketplace1 (www.biosigtech.com).
Led by a proven management team and a veteran, independent Board of
Directors, Minneapolis-based BioSig Technologies is preparing to
commercialize its PURE EP System.
The PURE EP System is a
surface electrocardiogram and intracardiac multichannel signal
acquisition and analysis system designed to assist electrophysiologists
in making clinical decisions in real-time by acquiring and displaying
high-fidelity cardiac signal recordings and providing clarity of data
which may be used to guide the electrophysiologists in identifying
ablation targets - areas of tissue to treat that otherwise create a
heart rhythm disturbance (arrhythmia).
Analysts forecast the
global market for EP devices will grow at a 12.1 percent compound
annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 20191,
making it one of the fastest growing medical device segments. Just in
the US, the number of Atrial Fibrillation (AF) and Ventricular
Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5
percent from 2012 to 20172.
BioSig intends to
seek FDA 510(k) clearance for the PURE EP System. The Company has
achieved proof of concept validation through UCLA labs, and has
performed pre-clinical studies at the Mayo Clinic in Minnesota. The
Company is collaborating with several of the nation's most prestigious
cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute,
UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
1Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
2HRI
2013 "Global Opportunities in Medical Devices & Diagnostics"
report; triangulation of multiple sources; AF includes left atrial
tachycardia, left WPW, left atrial flutter.
About Minnetronix
Minnetronix
is a medical technology and innovation company with deep expertise in
electronic and electromechanical devices. Founded in 1996, the company
creates new technologies and therapies that solve unmet clinical and
business needs for patients and medical device companies. Minnetronix is
FDA Registered and ISO 13485 Certified.
No comments:
Post a Comment